38588-43-1

Upstream product

• 1553-60-2 ibufenac 
• 538-93-2 1-phenyl-2-methylpropane 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 21464-32-4 3-[(4-isobutyl-phenyl)-acetyl]-4-phenyl-3,4-dihydro-1H-benzo[d][1,2]oxazine 
• 21464-31-3 3-benzoyl-4-phenyl-3,4-dihydro-1H-benzo[d][1,2]oxazine 
• 110319-73-8 N-Hydroxy-2-(4-isobutyl-phenyl)-N-methyl-acetamide 
• 136436-83-4 (4S)-3-<2'-(4-isobutylphenyl)ethanoyl>-4-(1-methylethyl)2-oxazolidinone 
• 136436-80-1 (4S)-3-<(s'S)-2'-(4-isobutylphenyl)propanoyl>-4-(1-methylethyl)-2-oxazolidinone 
• 135360-27-9 2-(3-Butoxy-phenoxy)-1-(4-isobutyl-phenyl)-ethanone oxime 
• 135360-26-8 2-(3-Butoxy-phenoxy)-1-(4-isobutyl-phenyl)-ethanone oxime 
• 155649-07-3 2-(4-Isobutyl-phenyl)-propionic acid (1R,3R,5S)-8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester 
• 71381-91-4 (+/-)-2-(4-isobutylphenyl)propanoyl chloride 
• 15687-27-1 ibuprofen 
• 915315-36-5 (4R,5S)-N-(4-isobutylphenyl acetyl)-4-methyl-5-phenyl-2-oxazolidinone 

Relevant academic research and scientific papers

Diastereoselective Electrophilic Trifluoromethylthiolation of Chiral Oxazolidinones: Access to Enantiopure α-SCF3 Alcohols

Lithium imide enolates featuring Evans’ chiral oxazolidinone auxiliary were involved in diastereoselective α-trifluoromethylthiolation with electrophilic SCF3 donors. Diastereopure products were isolated and converted to enantiopure α-SCF3 alcohols without racemisation. (Figure presented.).

A novel asymmetric synthesis of tritium and carbon-14 labeled (R)-ibuprofen

An efficient asymmetric synthesis of tritium and carbon-14 labeled R-ibuprofen was achieved in good overall yield (15% and 47%, respectively) and excellent enantiomerical excess (>98% e.e.), using (4R, 5S)-4-methyl-5- phenyl-2-oxazolidinone as a chiral au

Design, Synthesis, and Biological Evaluation of New 8-Heterocyclic Xanthine Derivatives as Highly Potent and Selective Human A2B Adenosine Receptor Antagonists

Here we report the synthesis of 8-heterocycle-substituted xanthines as potent and selective A2B adenosine receptor antagonists. The structure-activity relationships (SAR) of the xanthines synthesized in binding to recombinant human A2B adenosine receptors (ARs) in HEK-293 cells (HEK-A2B) and at other AR subtypes were explored. The synthesized compounds showed A2B adenosine receptor affinity in the nanomolar range and good levels of selectivity evaluated in radioligand binding assays at human (h) A1, A2A, A2B, and A3 ARs. We introduced several heterocycles, such as pyrazole, isoxazole, pyridine, and pyridazine, at the 8-position of the xanthine nucleus and we have also investigated different spacers (substituted acetamide, oxyacetamide, and urea moieties) on the heterocycle introduced. Various groups at the 3- and 4-positions of phenylacetamide moiety were studied. This study allowed us to identify the derivatives 2-(3,4-dimethoxyphenyl)-N-[5-(2,6-dioxo-1,3-dipropyl-2,3,6, 7-tetrahydro-1H-purin8-yl)-1-methyl-1H-pyrazol-3-yl] acetamide (29b, MRE2028F20) [Ki(hA2B) = 38 nM, Ki(hA1,hA 2A,-hA3) >1000 nM], N-benzo[1,3]dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6, 7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy] acetamide (62b, MRE2029F20) [Ki(hA2B) = 5.5 nM, Ki(hA 1,hA2A,hA3) > 1000 nM], and N-(3,4-dimethoxyphenyl)-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6, 7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy] acetamide (72b, MRE2030F20) [Ki(hA2B = 12 nM, Ki(hA 1,hA2A, hA3) > 1000 nM], which showed high affinity at the A2B receptor subtype and very good selectivity vs the other ARs. Substitution of the acetamide with an urea moiety afforded bioisosteric xanthines with good affinity and selectivity comparable to the acetamide derivatives. Substitution at the para-position of a 4-benzyloxy group of the phenylacetamido chain enhanced affinity at the A2B receptor [compound 30b (Ki(hA2B) = 13 nM) vs compound 21b (K i(hA2B = 56 nM)] but did not favor selectivity. The derivatives with higher affinity at human A2B AR proved to be antagonists, in the cyclic AMP assay, capable of inhibiting the stimulatory effect of NECA (100 nM) with IC50 values in the nanomolar range, a trend similar to that observed in the binding assay (62b, IC50 = 38 nM; 72b, IC50 = 46 nM). In conclusion, the 8-pyrazolo-1,3-dipropyl-1H-purine-2,6-dione derivatives described herein represent a new family of selective antagonists for the adenosine A 2B receptor.

Conversion of cyclooxygenase inhibitors into hydroxythiazole 5-lipoxygenase inhibitors

Representative examples of NSAID cyclooxygenase inhibitors such as naproxen, ibufenac, ibuprofen, and butibufen have been transformed into 5-lipoxygenase inhibitors by replacement of the carboxylic acid moiety with a 4-hydroxythiazole group.

Presynaptic cholinergic modulators as potent cognition enhancers and analgesic drugs. 1. Tropic and 2-phenylpropionic acid esters

Previous studies have shown that (R)-(+)-hyoscyamine has analgesic activity as a consequence of increased ACh release following antagonism of central muscarinic autoreceptors. Since the enhancement of central cholinergic transmission could be beneficial for cognitive disorders, we manipulated (R)-(+)-hyoscyamine, synthesizing several derivatives of tropic and 2-phenylpropionic acids, with the aim of obtaining drugs which are able to increase ACh release and consequently to show analgesic and nootropic activities. The results showed that several new compounds are indeed potent analgesics (with an analgesic efficacy comparable to that of morphine) and that the most potent one ((±)-19, PG9) also has remarkable cognition- enhancing properties. Our study confirmed that the mechanism of action involves ACh release even if it is still unclear whether only muscarinic autoreceptors or, also, heteroreceptors are involved.

Asymmetric synthesis of 2-arylpropionic acids

The preparation of (S)-2-(6-methoxy-2-naphtyl)propionic acid (S-Naproxen) 1 and (S)-2-(4-isobutylphenyl)propionic acid (S-Ibuprofen) 2, based on asymmetric alkylation of oxazolidinones 9 and 14, is reported.

SYNTHESIS OF N--ACETOHYDROXAMIC ACIDS, POTENTIAL INHIBITORS OF THE 5-LIPOXYGENASE

The synthesis of the title compounds starts from methyl (3-subst.phenoxy)alkanoates II which are reduced to the corresponding aldehydes and then transformed to oximes V by reaction with hydroxylamine.Reduction with borane-pyridine complex gives the hydroxylamines VI which on diacetylation and partial deacetylation provide the hydroxamic acids VIII.

In Vivo Characterization of Hydroxamic Acid Inhibitors of 5-Lipoxygenase

The hydroxamic acid functionality can be incorporated into simple molecules to produce potent inhibitors of 5-lipoxygenase.The ability of many of these hydroxamates to inhibit leukotriene synthesis in vivo has been measured directly with a rat peritoneal anaphylaxis model.Despite their potent enzyme inhibitory activity in vitro, many orally dosed hydroxamic acids only weakly inhibited leukotriene synthesis in vivo.This discrepancy is attributable at least in part to the rapid metabolism of hydroxamates to the corresponding carboxylic acids, which are inactive against the enzyme.A study of the structural features that affect this metabolism revealed that 2-arylpropionohydroxamic acids are relatively resistant to metabolic hydrolysis.Several members of this class of hydroxamates are described that are orally active inhibitors of leukotriene synthesis.